Title:
PHARMACEUTICAL COMPOSITION
Document Type and Number:
WIPO Patent Application WO/2019/065720
Kind Code:
A1
Abstract:
The present invention relates to a pharmaceutical composition which contains an anti-PD-L1 antibody as an active ingredient and is characterized by being used in combination with camptothecin and/or a derivative thereof or a pharmaceutically acceptable salt of camptothecin and/or the derivative.
More Like This:
Inventors:
IWAI TOSHIKI (JP)
YAMAMOTO KANAME (JP)
SUGIMOTO MASAMICHI (JP)
YAMAMOTO KANAME (JP)
SUGIMOTO MASAMICHI (JP)
Application Number:
PCT/JP2018/035655
Publication Date:
April 04, 2019
Filing Date:
September 26, 2018
Export Citation:
Assignee:
CHUGAI PHARMACEUTICAL CO LTD (JP)
International Classes:
A61K39/395; A61K31/4745; A61P35/00; A61P35/02; A61P43/00
Domestic Patent References:
| WO2017049199A1 | 2017-03-23 | |||
| WO2017049199A1 | 2017-03-23 |
Other References:
HIROO SATO, ET AL.: "Elucidation of DNA repair mechanism leading to enhancement of anti-tumor effect of immune checkpoint inhibitor during radiation therapy", 20 October 2016 (2016-10-20), XP055587536, Retrieved from the Internet
ASANUMA HIROKO : "P1−37: Expression analysis of PD-L1 in breast cancer stem cells and tumor tissues", JAPANESE JOURNAL OF CLINICAL IMMUNOLOGY, vol. 39, no. 4, 2016, pages 393, XP009519908, DOI: 10.2177/jsci.39.393a
"Irinotecan hydrochloride injection 40mg / 100mg", June 2014 (2014-06-01), XP055587555, Retrieved from the Internet [retrieved on 20181011]
IWAI, TOSHIKI ET AL.: "Topoisomerase I inhibitor, irinotecan, depletes regulatory T cells and up-regulates MHC class I and PD-L1 expression, resulting in a supra-additive antitumor effect when combined with anti-PD-Ll antibodies", ONCOTARGET, vol. 9, no. 59, 2018, pages 31411 - 31421, XP055587542
See also references of EP 3689376A4
ASANUMA HIROKO : "P1−37: Expression analysis of PD-L1 in breast cancer stem cells and tumor tissues", JAPANESE JOURNAL OF CLINICAL IMMUNOLOGY, vol. 39, no. 4, 2016, pages 393, XP009519908, DOI: 10.2177/jsci.39.393a
"Irinotecan hydrochloride injection 40mg / 100mg", June 2014 (2014-06-01), XP055587555, Retrieved from the Internet
IWAI, TOSHIKI ET AL.: "Topoisomerase I inhibitor, irinotecan, depletes regulatory T cells and up-regulates MHC class I and PD-L1 expression, resulting in a supra-additive antitumor effect when combined with anti-PD-Ll antibodies", ONCOTARGET, vol. 9, no. 59, 2018, pages 31411 - 31421, XP055587542
See also references of EP 3689376A4
Attorney, Agent or Firm:
TSUKUNI & ASSOCIATES et al. (JP)
Download PDF: